The impact of progression‐directed therapy on survival in metastatic castration‐refractory prostate cancer: MEDCARE phase 3 trial
This is the first randomised phase 3 trial in the setting of PDT in patients with oligoprogressive mCRPC with OS as the primary endpoint.
Authors
- Steven Joniau (ORCID: https://orcid.org/0000-0003-3195-9890)
- Lodewijk Van Wynsberge (ORCID: https://orcid.org/0000-0002-7926-1179)
- Karolien Goffin (ORCID: https://orcid.org/0000-0002-7453-0229)
- Gert De Meerleer (ORCID: https://orcid.org/0000-0002-2891-6235)
- Gedske Daugaard (ORCID: https://orcid.org/0000-0002-9618-9180)
- Kato Rans (ORCID: https://orcid.org/0000-0002-0389-4041)
- J. M. Hartog
Institutions
- Universitair Ziekenhuis Leuven (BE)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Soltech (Belgium) (BE)
- KU Leuven (BE)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2024-11-06
- DOI
- https://doi.org/10.1111/bju.16574
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.84